Perforation of the Atrial Wall and Aortic Sinus after Closure of an Atrial Septal Defect with an Atriasept Occluder: A Case Report

Zaiqiang Zhang
Institute of Cardiovascular Diseases China Three Gorges University

Jia-Wang Ding (dingjiawang@163.com)
Institute of Cardiovascular Diseases, China Three Gorges University

Case report

Keywords: atrial septal defect (ASD), percutaneous intervention, Amplatzer septal occluder (ASO), atrial and aortic erosion

DOI: https://doi.org/10.21203/rs.3.rs-92127/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: While the perforation of the atrial wall and aortic sinus after closure of an atrial septal defect (ASD) is rare, it's life-threatening, with rapid progress and high mortality. To the best of our knowledge, 21 similar cases have been reported since 1976.

Case presentation: We report a 16-year-old male whose atrial septal defect (ASD) was closed using a 12-mm Amplatzer septal occluder (ASO). Atrial wall and aortic sinus perforation occurred 3 months after transcatheter closure, and the patient was discharged after emergency operation. He was discharged on the 12th postoperative day in good overall condition.

Conclusions: With this case report, we want to illustrate that although percutaneous closure of ASD is regarded as a routine procedure, we should not forget the potentially lethal complications, especially cardiac erosion. Therefore, we should carefully evaluate the risk of erosion before surgery, and careful lifelong follow-up is needed.

Background

In recent years, large-scale epidemiological studies have found that the prevalence of congenital heart disease (CHD) is 9 per 1000 newborns worldwide, and atrial septal defect (ASD) accounts for approximately 6 to 10% of all CHD in children and for 30% of all CHD in adult patients[1]. With the continuous development of the transcatheter approach, the use of the transcatheter device technique has become widely accepted as an alternative therapy to surgery. It has proven to be as effective as surgical ASD closure and offers significant benefits in terms of low invasiveness, shorter hospitalization, and fewer complications. Erosion is a rare but severe complication of transcatheter ASD closure that occurs in 0.2% of patients[2]. Aortic rim deficiency and implantation of an oversized device are risk factors for erosion. Here, we report a case of perforation of the atrial wall and aortic sinus after closure of an atrial septal defect with an Atriasept occluder.

Case Presentation

A 16-year-old boy presented with a history of chest tightness for 3 years. Clinical examination favored a diagnosis of an ASD with a left-to-right shunt. Transthoracic echocardiography (TTE) (Fig. 1A) and echocardiography of the right heart (Fig. 2A) confirmed the diagnosis and delineated the morphology of the ASD. He was scheduled for transesophageal echocardiography (TEE) (Fig. 2B), and the ASD measured 0.6 cm. The septal rim was at least 5 mm from the right pulmonary veins, superior vena cava, os of the coronary sinus, and mitral valve. The cardiac Computed tomography (CT) showed a small ASD (Fig. 3). The laboratory examination and electrocardiogram (ECG) showed no abnormalities. The patient underwent cardiac catheterization and device closure with an Amplatzer septal occluder (ASO) (AGA Medical, USA). Balloon sizing was performed under fluoroscopic and TTE guidance. The ASD measured 6 mm, and accordingly, a 12-mm ASO device was selected and deployed successfully across the defect
by the conventional technique as described previously. After confirmation of the position and stability of the device on fluoroscopy and TTE, it was released (Fig. 4). The patient underwent a predischarge TTE study on postintervention day 7 (Fig. 1B). The device straddled the ASD well, and there was no obvious shunt on color-flow mapping. No short-term complications occurred, and further follow-up remained uneventful.

Three months later, the patient suddenly developed chest pain that could not be relieved. The ECG obtained at admission showed no abnormality. The laboratory examination results were as follows: blood potassium (K⁺) 3.27 mmol/L; cardiac troponin I (cTn I) 1.67 ng/ml; creatine kinase (CK) 2362 U/L; creatine kinase-MB (CKMB) 6.6 ng/ml; serum creatinine 153 µmol/L; D-dimer 0.79 µg/ml. Blood examination showed leukocytosis. The patient's blood pressure (BP) was 94/57 mmHg, and his heart rate was 95 bpm. Emergency echocardiography was performed immediately and showed a large amount of pericardial effusion. Cardiac CT showed changes after transcatheter closure of the atrial septal defect and moderate pericardial effusion (Fig. 5). The patient, in shock, underwent urgent operation. Intraoperative examination revealed rupture of the right atrial roof and noncoronary aortic sinus caused by the ASO. We placed a temporary pledgeted suture on the ruptured noncoronary sinus of the ascending aorta to stop the bleeding through a very small perforation. After standard bicaval cannulation, we initiated cardiopulmonary bypass. The right atrium was opened after aortic cross-clamping and antegrade delivery of blood cardioplegia. The ASO was then removed, and a temporary autologous pericardial patch was constructed for the ostial secundum ASD. Finally, the right atrial and noncoronary aortic sinus walls were primarily repaired. The patient was extubated on the first postoperative day, and no neurologic or other major sequelae were seen. He was discharged on the 12th postoperative day in good overall condition. Color Doppler ultrasound showed no pericardial effusion or shunt at the atrial level postoperatively.

**Discussion And Conclusions**

Percutaneous ASD closure has established itself as a routine intervention due to the effectiveness and safety of the procedure as well as the advantage of a short learning curve. Rupture of the free right atrial wall must be considered a severe complication of percutaneous CHD interventions. This may be a potentially life-threatening complication if it leads to cardiac tamponade. Atrial erosion has been reported in association with Amplatzer septal occluders[3, 4]. According to the data reviewed by Pediatric and Adult Interventional Cardiac Symposium (PICS) 2012[5], most of the erosion occurred near the aortic root and the top of the atrium: 47 cases involved perforation of the roof of the left atrium (28 cases involved the aorta), 26 cases involved perforation of the roof of the right atrium (22 cases involved the aorta), and 9 cases involved both atria; in 15 cases, the site was unknown. Similarly, in Pics 2012 data[5], approximately 87.6% of erosions occurred in the first year after implantation. The incidence of erosions in children was 57% within 72 hours after the operation, and it was 65% in adults after more than 72 hours after implantation.
Our case demonstrated perforation of the atrial wall and aortic sinus as a complication of the atrial septal defect closure device 3 months after implantation of a 12-mm ASO. Since erosion occurs several hours or even days after a successful transcatheter closure, it can be concluded that the damage mechanism is not related to a catheterization technique-related complication but rather to a complex interaction between the device and the atrial wall. According to previous experience with occlusion, the base of the aorta is adjacent to the anterosuperior rim or limbus of the defect. In some cases,[6] it is the only structure of this boundary. Due to the position of the device against the interatrial septum, the anterosuperior aspect of the device is in constant contact with the aorta during the cardiac cycle[7]. Moreover, due to defects in the aortic rings, especially with the deployment of a significantly oversized device, the edge of the device may elongate the free atrial wall adjacent to the atrial septum. With each cardiac cycle, the movement of the edge of the device near the superior edge leads to a "seesaw" mechanism, resulting in potential erosion of the atrial roof and the adjacent aorta. The result is the development of pericardial hemorrhage and hemodynamic damage. The vulnerability of the atrial wall becomes more exaggerated with oversizing of the device and reduction of the RA cavity after ASD closure[8]. We also found that compared with other atrial septal occluders, AGA occluder material has greater hardness. If placed near the aortic wall, this structure will lead to more rigid contact with the atrial wall and aortic wall, resulting in a higher risk of atrial and aortic erosion.

However, the current analysis of and theory on how device erosion occurs have significant limitations. Therefore, we should pay attention to the following points in future transcatheter closure: first, we should rigorously identify the indications before the operation; second, we must improve transthoracic echocardiography and transesophageal echocardiography before the operation to preoperatively assess the morphology of the ASD with respect to its location, size, shape, and margins and select the appropriate occluder according to the examination results; third, since events are more frequent in the first year, there should be frequent follow-up in the first year (e.g., serial echocardiography at 1 week, 1 month, 3 months, and 6 months) and clinical follow-up annually with less frequent follow-up after the first year[9]; fourth, clinicians must ensure that patients are well informed of the risks/benefits of transcatheter closure of ASD. Further, sufficient communication between clinicians and their patients who have undergone implantation should be occur to educate patients about symptoms without creating fear and anxiety.

To summarize, with this case report, we want to illustrate that although percutaneous closure of ASD is regarded as a routine procedure, we should not forget the potentially lethal complications, especially cardiac erosion. Therefore, we should carefully evaluate the risk of erosion before surgery, and careful lifelong follow-up is needed.

**Abbreviations**

ASD: Atrial septal defect; ASO: Amplatzer septal occlude; CHD: Congenital heart disease; TTE: Transthoracic echocardiography; TEE: Transesophageal echocardiography; ECG: Electrocardiogram; CT:
Declarations

Acknowledgements

Not applicable.

Authors’ contributions

ZQZ wrote the manuscript. ZQZ and JWD obtained the image data. All authors were involved in the treatment of the patient. All authors read and approved the final written manuscript.

Funding

National Natural Science Foundation of China (Grant No. 81770456).

Availability of data and materials

The datasets of the current study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate

The ethics committee of the First College of Clinical Medical Science, China Three Gorges University approved the study.

Consent for publication

Consent for publication is obtained from the patient.

Competing interests

The authors declare that they have no competing interests.

References

1. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2020.

2. Crawford GB, Brindis RG, Krucoff MW, Mansalis BP, Carroll JD. Percutaneous atrial septal occluder devices and cardiac erosion: a review of the literature. Catheter Cardiovasc Interv. 2012;80(2):157-67.

3. Turner DR, Owada CY, Sang CJ, Khan M, Lim DS. Closure of Secundum Atrial Septal Defects With the AMPLATZER Septal Occluder: A Prospective, Multicenter, Post-Approval Study. Circ Cardiovasc Interv. 2017;10(8).
4. Kenny D, Eicken A, Dähnert I, Boudjemline Y, Sievert H, Schneider MB, et al. A randomized, controlled, multi-center trial of the efficacy and safety of the Occlutech Figulla Flex-II Occluder compared to the Amplatzer Septal Occluder for transcatheter closure of secundum atrial septal defects. Catheter Cardiovasc Interv. 2019;93(2):316-21.

5. Diab K, Kenny D, Hijazi ZM. Erosions, erosions, and erosions! Device closure of atrial septal defects: how safe is safe. Catheter Cardiovasc Interv. 2012;80(2):168-74.

6. El-Said HG, Moore JW. Erosion by the Amplatzer septal occluder: experienced operator opinions at odds with manufacturer recommendations. Catheter Cardiovasc Interv. 2009;73(7):925-30.

7. Dardas PS, Ninios VN, Mezilis NE, Tsikaderis DD, Thanopoulos VD. Percutaneous closure of atrial septal defects: immediate and mid-term results. Hellenic J Cardiol. 2010;51(2):104-12.

8. Haas NA, Soetemann DB, Ates I, Baspinar O, Dikivskyy I, Duke C, et al. Closure of Secundum Atrial Septal Defects by Using the Occlutech Occluder Devices in More Than 1300 Patients: The IRFACODE Project: A Retrospective Case Series. Catheter Cardiovasc Interv. 2016;88(4):571-81.

9. Boudoulas KD, Marmagkiolis K, Boudoulas H. Atrial Septal Defect Sizing and Transcatheter Closure. Cardiology. 2019;142(2):105-8.